Cutting-edge devices in Japan may qualify for special reimbursement criteria, such as the Premium for New Technology. To qualify, devices must demonstrate significant clinical innovation, improved patient outcomes, or cost-effectiveness beyond existing technologies. MHLW and Chuikyo evaluate robust evidence during the reimbursement process, often granting higher pricing under the NHI system.
